Schedule 13D ownership disclosure
DRUGS MADE IN AMERICA ACQUISITION II CORP. CMN
Ordinary Shares · CUSIP: G2851K104
Event date: 2025-10-01
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Drugs Made In America Acquisition II LLCReported CIK 0002088432
Shares: 6,708,333.00 · Class: 10.2%
- Lynn StockwellReported CIK 0001927032
Shares: 6,708,333.00 · Class: 10.2%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001213900-25-094944
- Form type
- SCHEDULE 13D
- Filer
- Drugs Made In America Acquisition II Corp.
- CIK
- CIK 2040475
- Filed
- Oct 02, 2025
- Reporting period
- Oct 01, 2025
- Description
- Schedule 13D beneficial ownership